Clinical Trials Logo

Clinical Trial Summary

Recent studies that ex vivo drug responses on PDO models across different solid tumours can predict treatment responses to chemotherapeutic agents. In patients with metastatic or inoperable solid abdominal tumours, we perform a PDO based drug screen and to identify drugs that will confer clinical response and compared to conventional treatments


Clinical Trial Description

Precision oncology aims to improve the clinical outcomes of patients by offering personalized treatment through identifying druggable genomic aberrations within their tumours. However, current challenges in cancer treatment have hampered the broad clinical utility of the gene-drug associations in the clinic. This is particularly valid when it comes to offering alternative treatment options for advanced inoperable patients with chemo-refractory diseases. There is currently no reliable biomarker to predict treatment response. Patient-derived organoids (PDOs) closely resemble both pheno- and genotypically to patients' tumours. In observational studies, anticancer drug screening ex vivo on PDOs has been shown to predict clinical response with high sensitivity and specificity. PDO-based drug screen represents a truly personalised platform by predicting patient-specific drug response with high accuracy. Recent technical advancements in growing these PDO 'avatars' from biopsies have made it possible to find anticancer drug options in tumours from advanced inoperable patients, and explore new possibilities for treatment options that otherwise would be missed by standard conventional therapies. PDO-based drug assays permit examination of combinatorial drug testing ex vivo and potentially offer patients treatment options. The clinical utility of treatment based on PDO informed drug options however has not been established. We hypothesize that treatment guided by PDO-based drug screens, when compared to conventional treatment, can lead to better treatment response and clinical outcomes. We propose a phase 2 proof-of-concept randomized controlled trial in patients with inoperable or metastatic abdominal tumours refractory to at least one chemotherapeutic agent. Our primary endpoint to this randomised trial is progression-free survival (PFS) at 12 months. In this trial, we in addition expand our current bio-resource of PDOs, and further valid PDO guided treatment model by comparing ex vivo PDO drug response to patients' clinical response. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05378048
Study type Interventional
Source Chinese University of Hong Kong
Contact
Status Withdrawn
Phase Phase 2
Start date July 4, 2022
Completion date July 3, 2025

See also
  Status Clinical Trial Phase
Completed NCT02888587 - The Innervation of Human Gut Sensory Epithelial Cells
Recruiting NCT06100003 - A Clinical Study Aims to Assess the Consistency of Clinical Efficacy in Gastric Cancer Treatment and Drug Susceptibility Outcomes Using a Novel Drug Susceptibility Testing Method
Recruiting NCT06100016 - A Clinical Study Aims to Assess the Consistency of Clinical Efficacy in Colorectal Cancer Treatment and Drug Susceptibility Outcomes Using a Novel Drug Susceptibility Testing Method
Recruiting NCT04996355 - Organoids-on-a-chip for Colorectal Cancer and in Vitro Screening of Chemotherapeutic Drugs
Recruiting NCT04279509 - Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE) N/A
Recruiting NCT04555473 - Translational Analysis In Longitudinal Series of Ovarian Cancer ORganoids
Recruiting NCT05323357 - Bern Human Organoid-Study to Study Host-microbe Interaction
Recruiting NCT06315868 - Breast Cancer Subtype Characterization Through Patient's Derived Organoids.
Not yet recruiting NCT05644743 - Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma
Recruiting NCT06155305 - Organoids Based Drug Sensitivity in Neoadjuvant Chemotherapy of Breast Cancer
Recruiting NCT03577808 - Organoids in Predicting Chemoradiation Sensitivity on Rectal Cancer
Recruiting NCT04906733 - Cetuximab Sensitivity Correlation Between Patient-Derived Organoids and Clinical Response in Colon Cancer Patients.